📬 Lung/Head and Neck/Thymoma Intelligence Digest — Week 2026-W36
HARMONi publishes in Lancet Oncology with PFS 6.8 vs 4.4 months but no significant OS, AEGEAN's update shows EFS HR 0.69 with OS HR 0.89, KEYNOTE-671 five-year data land in Annals of Oncology, and an Annals analysis of 1,107 patients links incidental thymic radiation to distant metastasis.
⚡ TL;DR
📄 Publications
- Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study. — Five-year EFS was 49.9% with pembrolizumab versus 26.5% with placebo (HR 0.58)
- Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial. — 124 patients aged 75 or older were enrolled, 61 to carboplatin and 63 to carboplatin plus nab-paclitaxel
- Concurrent chemotherapy and external radiation therapy (ConCERT): phase 3 noninferiority randomized clinical trial of cisplatin weekly vs every 3 weeks in locally advanced squamous cell carcinoma of the head and neck. — 278 patients were enrolled, 137 standard and 141 experimental arm, with median follow-up 43.9 months
- Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. — 438 patients were randomly assigned 1:1 across 114 centres in Asia, Europe and North America
- Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial. — At a median follow-up of 25.9 months, EFS benefit favored durvalumab with HR 0.69 (95% CI 0.55 to 0.88)
🐦 Twitter / 🦋 Bluesky
- Update: KEYNOTE-671's five-year paper lands in Annals of Oncology, and the debate turns to who can skip the adjuvant phase — Five-year EFS was 49.9% versus 26.5% (HR 0.58) and five-year OS 64.6% versus 53.6% (HR 0.74), with no detriment to quality of life
- Annals of Oncology analysis of 1,107 patients links incidental thymic radiation to distant metastasis, putting the thymus on the thoracic RT planning list — Across 3 cohorts of locally advanced NSCLC (n=1,107), higher thymic radiation dose was associated with increased distant metastasis risk, and in the CRT-to-durvalumab cohort mean thymic dose >35 Gy nearly doubled the risk (HR 1.96)
- HARMONi publishes in Lancet Oncology: a PD-1×VEGF bispecific halves progression risk after osimertinib but misses on overall survival eight weeks before its PDUFA date — Median PFS was 6.8 versus 4.4 months (HR 0.52, p<0.001) and median OS 16.8 versus 14.0 months (HR 0.79, p=0.057), not statistically significant
- Update: Panku-Lung01's positive PFS readout for the EGFR-HER3 bispecific ADC iza-bren draws detail on the trial design and the global follow-on program — The phase III Panku-Lung01 study of iza-bren versus platinum doublet chemotherapy was positive in EGFR-mutant NSCLC post TKI, showing superior PFS with an OS trend per press release
- Update: the RAS-resistance analysis draws wider comment as an Annals review of RAS-mediated resistance in oncogene-driven lung cancer goes into press — RAS alterations emerge in about 10% of EGFR-mutant NSCLC at osimertinib resistance, with KRAS G12D enriched and G12C notably rare
Full details below ↓
📄 What's Being Published
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study. — Wakelee H et al., Ann Oncol
In 797 randomized participants (397 pembrolizumab, 400 placebo), five-year EFS was 49.9% (95% CI, 44.6–55.0) versus 26.5% (95% CI, 21.7–31.5) in favor of pembrolizumab (HR 0.58; 95% CI, 0.48–0.69). Five-year OS was 64.6% (95% CI, 59.5–69.2) versus 53.6% (95% CI, 48.3–58.6; HR 0.74; 95% CI, 0.59–0.92), and no detriment to health-related quality of life was identified in the pembrolizumab versus placebo arm with longer follow-up.
Clinical bottom line: With five years of follow-up now published, perioperative pembrolizumab nearly doubles event-free survival and keeps improving overall survival without a quality-of-life cost, and the argument has moved to who still needs the adjuvant half.
Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial. — Omori Shota et al., Lung Cancer
From December 2020 to March 2024, 124 patients were enrolled (61 to the carboplatin arm, 63 to carboplatin plus nab-paclitaxel). At a planned interim analysis, the Bayesian predictive probability of non-inferiority for the doublet was 8.0%, triggering early termination for futility; estimated median OS in the carboplatin plus nab-paclitaxel arm was 26.1 months (HR 1.56; 95% CI, 0.79–3.11; p = 0.200). Quality of life at 6 weeks favored the carboplatin monotherapy arm (odds ratio 0.39; 95% CI, 0.18–0.81; p = 0.012).
Clinical bottom line: Daily low-dose carboplatin with thoracic radiotherapy stays the standard for patients aged 75 and over with unresectable locally advanced NSCLC: the weekly carboplatin plus nab-paclitaxel doublet was stopped for futility and delivered worse early quality of life.
Concurrent chemotherapy and external radiation therapy (ConCERT): phase 3 noninferiority randomized clinical trial of cisplatin weekly vs every 3 weeks in locally advanced squamous cell carcinoma of the head and neck. — Sharma Atul et al., J Natl Cancer Inst
278 patients were enrolled (137 standard 3-weekly arm, 141 experimental weekly arm) with a median follow-up of 43.9 months; 272 were eligible for final analysis. Two-year locoregional control rates were 61.3% (weekly) versus 51.1% (3-weekly), an absolute difference of 10.2% within the non-inferiority margin (HR 0.72; 95% CI, 0.50–1.05; P = 0.091), with median OS 24.9 versus 22.2 months (P = 0.501). Grade 3 or higher adverse events were less frequent with weekly cisplatin (44.7% vs 60.7%; P = 0.018), as were hospitalisations (20.3% vs 36.8%; P = 0.004).
Clinical bottom line: Weekly cisplatin 40 mg/m² is non-inferior to 3-weekly 100 mg/m² for 2-year locoregional control in non-nasopharyngeal locally advanced head and neck cancer and causes fewer severe toxicities and hospitalisations, so it should be the default for patients where high-dose tolerance is in doubt.
SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. — Zhong Runbo et al., Lancet Oncol
395 patients were enrolled and treated, including 197 with non-small cell lung cancer and 26 with head-and-neck squamous-cell carcinoma. Grade 3–4 treatment-related adverse events were reported in 212 (54%) of 395 patients, most commonly decreased neutrophil count (30%), decreased white-blood-cell count (19%), and anaemia (17%). During dose escalation, one dose-limiting toxicity was reported at 10 mg/kg (grade 4 decreased platelet count) and the maximum tolerated dose was not reached.
Clinical bottom line: The nectin-4 ADC SHR-A2102 is tolerable at 6–8 mg/kg with a topoisomerase-I-inhibitor toxicity profile dominated by myelosuppression, and the lung and head-and-neck cohorts within this 395-patient phase 1 are the ones worth following into randomized testing.
AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. — Xing Ligang et al., J Immunother Cancer
63 patients were randomized to arms A (N=22), B (N=19), and C (N=22) before early trial termination. Median PFS was not reached in arm A, 15.0 months (95% CI, 7.4 to not estimable) in arm B, and 10.4 months (95% CI, 5.7 to not estimable) in the concurrent chemoradiotherapy-then-durvalumab arm C. Pneumonitis occurred in 18.2% of arm A, 5.6% of arm B, and 9.1% of arm C, with interstitial lung disease in 13.6%, 11.1%, and 0% respectively, the majority of events grade 1/2.
Clinical bottom line: AdvanTIG-301 closed after only 63 patients, so its numerical hint that concurrent tislelizumab with or without the anti-TIGIT ociperlimab beats sequential durvalumab is descriptive only and cannot displace consolidation durvalumab after chemoradiation.
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. — Le Xiuning et al., Lancet Oncol
438 patients were enrolled and randomly assigned to receive ivonescimab plus chemotherapy or placebo plus chemotherapy (219 per group). Median progression-free survival was 6.8 months (95% CI, 5.7–7.1) in the ivonescimab plus chemotherapy group versus 4.4 months (95% CI, 4.1–5.5) in the placebo plus chemotherapy group (HR 0.52; 95% CI, 0.41–0.66; p<0.0001). Median overall survival was 16.8 months (95% CI, 14.3–19.0) versus 14.0 months (95% CI, 12.8–15.7; HR 0.79; 95% CI, 0.62–1.01), and serious treatment-related adverse events occurred in 28% of the ivonescimab group versus 15% with placebo.
Clinical bottom line: HARMONi gives the first global randomized phase 3 evidence that a PD-1×VEGF bispecific plus chemotherapy halves the risk of progression after third-generation EGFR-TKI failure, but the overall survival curve separates without reaching significance and serious toxicity nearly doubles, so the November FDA decision will turn on how much weight PFS alone can carry.
Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma. — Ruan Dan-Yun et al., J Clin Oncol
Among 31 patients with nasopharyngeal carcinoma at the recommended phase II dose who had received anti-PD-1/PD-L1 and platinum-based therapy, the confirmed ORR was 71.0% (95% CI, 52.0–85.8) and DCR was 93.5% (95% CI, 78.6–99.2). Median duration of response was 14.0 months (95% CI, 5.7 to not estimated) and median PFS 12.0 months (95% CI, 6.8–15.4). Grade 3 or higher treatment-related adverse events occurred in 40.6% of patients with no treatment-related deaths.
Clinical bottom line: An EGFR-directed ADC combined with a PD-1 inhibitor produced a 71% response rate with 12-month PFS in platinum- and checkpoint-resistant nasopharyngeal carcinoma, making anti-PD-1 rechallenge alongside ADC a serious strategy for a setting that currently has none, pending the ongoing randomized phase III.
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial. — Heymach John V et al., J Clin Oncol
As of May 10, 2024 (median follow-up 25.9 months for censored patients), EFS benefit favoring the durvalumab arm remained consistent (HR 0.69; 95% CI, 0.55–0.88), with a numerical improvement in DFS (HR 0.66; 95% CI, 0.47–0.92) and OS (HR 0.89; 95% CI, 0.70–1.14) also favoring the durvalumab arm. Efficacy was analyzed in a modified intention-to-treat population of 740 patients excluding those with documented EGFR/ALK aberrations. Maximum grade 3/4 adverse events during adjuvant treatment occurred in 15.4% of durvalumab and 10.6% of placebo patients.
Clinical bottom line: The second interim analysis holds AEGEAN's EFS benefit at HR 0.69 but leaves overall survival at HR 0.89 and unproven, so the trial still cannot answer whether the adjuvant durvalumab half contributes anything.
Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial. — Wu Fengying et al., J Thorac Oncol
In 99 enrolled patients, the IRC-confirmed ORR was 70.8% (95% CI, 60.7–79.7) and DCR 90.6% (95% CI, 82.9–95.6), with median duration of response 12.0 months (95% CI, 9.3–15.7) and median PFS 13.7 months (95% CI, 10.9–16.4). ORR was numerically higher in patients with compound versus solitary uncommon EGFR mutations (84.4% vs 64.1%), with median PFS 13.8 versus 11.0 months respectively. Grade 3 or higher treatment-related adverse events occurred in 42.4%, most commonly diarrhea at 28.3%.
Clinical bottom line: Sutetinib delivers a 70.8% response rate and 13.7-month PFS in G719X/S768I/L861Q NSCLC, the best prospective first-line evidence yet for uncommon EGFR mutations, but grade 3 diarrhea in 28% means dose management will decide whether it is usable.
Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial. — Dziadziuszko Rafal et al., Lancet Oncol
257 patients were randomised (130 to alectinib, 127 to chemotherapy); discontinuations due to adverse events were fewer with alectinib (5%) than chemotherapy (13%), and serious treatment-related adverse events occurred in 2% versus 7% respectively. At week 96, mean Mental Component Summary score was 49.9 (SD 10.4) and Physical Component Summary score 48.8 (SD 7.2), reaching levels similar to the general population norm of 50. Improvements in physical and mental health-related quality of life were maintained over two years of active treatment.
Clinical bottom line: Two years of adjuvant alectinib is not just more effective than chemotherapy in resected ALK-positive NSCLC — patients feel better on it, with quality of life at population-norm levels and half the discontinuation rate, which removes the last practical objection to using it.
The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). — Kim Hye Sung et al., Lung Cancer
Of 606 patients, 277 (46%) had EGFR L858R, 384 (63%) had TP53 co-mutations, and 186 (30.7%) had both. Patients with both L858R and TP53 mutation had median real-world PFS of 10.1 versus 21.4 months (HR 2.2; P < 0.001) and OS of 21.3 versus 53.4 months (HR 2.3; P < 0.001) compared with patients with neither marker (exon 19 deletion/TP53-wildtype). In multivariate analysis, bearing L858R versus exon 19 deletion predicted inferior real-world PFS (HR 1.4; P = 0.001) and OS (HR 1.3; P = 0.01), as did TP53 co-mutation versus wildtype (rwPFS: HR 1.5; P < 0.001; OS: HR 1.6; P < 0.001).
Clinical bottom line: Combining EGFR subtype with TP53 status splits front-line osimertinib outcomes by more than 30 months of median survival, so this two-variable stratification should be routine when deciding who needs intensified therapy or a trial.
🗂 Every paper considered this week, including the ones that didn’t make it →
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
Update: KEYNOTE-671's five-year paper lands in Annals of Oncology, and the debate turns to who can skip the adjuvant phase
Five-year EFS of 49.9% versus 26.5% (HR 0.58) and five-year OS of 64.6% versus 53.6% (HR 0.74), with no detriment to quality of life, mark the published KEYNOTE-671 update — a result that one reading frames as immunotherapy doubling EFS at five years, adding as much benefit as surgery and chemotherapy combined, with approximately 1 in 10 patients cured by the added immunotherapy. Because no adjuvant immunotherapy trial has yet shown an OS benefit, one argument holds that all relevant patients should be considered for neoadjuvant or perioperative approaches. Clinicians are asking who needs neoadjuvant-only versus perioperative therapy, whether the adjuvant phase is needed and for how long, and whether PD-L1, pathological complete response, or ctDNA/MRD can guide selection.
Discussed by: @kazuki_nozawa, @BalazsHalmosMD, @StephenVLiu, @EladSharonMD, @HHorinouchi, @Dr_Oncologista
Annals of Oncology analysis of 1,107 patients links incidental thymic radiation to distant metastasis, putting the thymus on the thoracic RT planning list
Across 3 cohorts of locally advanced NSCLC — RTOG-0617 (n=460), HARVARD-CRT (n=422), and a CRT-to-durvalumab cohort (n=225) — totalling 1,107 patients, higher thymic radiation dose was associated with increased distant metastasis risk, particularly in patients with preserved thymic function; in the CRT-to-durvalumab cohort, mean thymic dose above 35 Gy was associated with a nearly doubled risk (HR 1.96; 95% CI, 1.24–3.11; P=0.004). Thymus-sparing replanning in 16 patients substantially reduced thymic exposure without meaningful compromise of target coverage or other organ-at-risk constraints. The 35 Gy threshold is described as exploratory rather than a validated planning constraint, but thymus-sparing radiotherapy is said to deserve prospective evaluation.
Discussed by: @jennifermarksmd, @jennifermarksmd, @OncoAlert, @ChandrakanthMv, @OncoAlert, @LungCancerEu
HARMONi publishes in Lancet Oncology: a PD-1×VEGF bispecific halves progression risk after osimertinib but misses on overall survival eight weeks before its PDUFA date
HARMONi — the first global randomized phase 3 study of a PD-1×VEGF bispecific antibody, with N=438 and 23% of patients enrolled in the United States — reported median PFS of 6.8 versus 4.4 months (HR 0.52; p<0.001) and median OS of 16.8 versus 14.0 months (HR 0.79; p=0.057), which was not statistically significant. Grade 3–5 treatment-related adverse events were 50% versus 42% and serious treatment-related adverse events 28% versus 15%, with PFS benefit consistent across subgroups including patients with brain metastases. An updated OS analysis to be presented at WCLC26 gives an OS HR of 0.76 — with the Western cohort median OS 17.5 versus 14.0 months (HR 0.76) and no new safety signals — and the FDA PDUFA date is November 14.
Discussed by: @RManochakian, @SandraOrtizCua1, @GlopesMd, @HHorinouchi, @HerediaOncologo, @Tony_Calles, @EgfrUk
Update: Panku-Lung01's positive PFS readout for the EGFR-HER3 bispecific ADC iza-bren draws detail on the trial design and the global follow-on program
The phase III Panku-Lung01 study of iza-bren — an EGFR-HER3 bispecific ADC — versus platinum doublet chemotherapy met its primary endpoint of PFS with a favorable trend also observed in OS in EGFR-sensitizing mutation-positive locally advanced or metastatic non-squamous NSCLC progressing on prior EGFR-TKI, per press release. Commentators connect this result to the BMS phase III Izabright-Lung01 and 02 programs, noting a prior phase II ORR of 100% for iza-bren plus osimertinib in the first-line setting. If iza-bren displaces platinum doublet chemotherapy as the post-TKI standard, it redefines the comparator arm for every subsequent trial in that population.
Discussed by: @EladSharonMD, @DrSanjayPopat, @peters_solange
Update: the RAS-resistance analysis draws wider comment as an Annals review of RAS-mediated resistance in oncogene-driven lung cancer goes into press
RAS alterations emerge in approximately 10% of EGFR-mutant NSCLC at osimertinib resistance, with KRAS G12D enriched and G12C notably rare; in patient-derived osimertinib-resistant models, combining osimertinib with zoldonrasib or daraxonrasib showed marked synergy and overcame RAS-mediated resistance. An article now in press in Annals of Oncology addresses therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer. The central question is whether RAS alterations should now be part of the standard re-biopsy panel at osimertinib progression, given this preclinical synergy with pan-RAS and G12D inhibitors.
Discussed by: @EladSharonMD, @jennifermarksmd
A 54-patient series of EGFR NSCLC transformed to small cell favors chemo-immunotherapy, and clinicians warn TKI and immunotherapy do not partner well
A retrospective report on 54 patients with EGFR NSCLC transformed to SCLC showed better outcomes with chemo-immunotherapy than chemotherapy alone, alongside a practical caution that immunotherapy and TKI do not partner well — so if a TKI is suppressing some disease including in the CNS, it would likely need to stop if immunotherapy were started. A WCLC26 mini-oral in EGFR-mutant NSCLC reported that neoadjuvant chemo-immunotherapy outperformed EGFR-TKI on pathologic response overall (pCR 19.6% vs 3.0%; MPR 41.2% vs 20.2%), with the gap driven by TP53-mutant patients (MPR 48.6% vs 9.6%), while TP53-wildtype patients showed the reverse (MPR 23.1% vs 38.7%). Some surgeons note they have long argued for a role for chemotherapy plus checkpoint inhibition in selected EGFR-mutant patients and faced criticism for doing so.
Discussed by: @StephenVLiu, @HHorinouchi, @BrendonStilesMD
AEGEAN's updated outcomes in JCO keep EFS at HR 0.69 while OS stays at HR 0.89, reviving the question of what the adjuvant durvalumab does
At 25.9 months median follow-up, AEGEAN's EFS HR is 0.69 (95% CI, 0.55–0.88), with median EFS not reached versus 30.0 months and 36-month EFS 60.1% versus 47.9%; DFS HR is 0.66 (95% CI, 0.47–0.92), narrowly missing the prespecified multiplicity-adjusted significance boundary; OS HR is 0.89 (95% CI, 0.70–1.14); lung-cancer-specific OS HR is 0.70 (95% CI, 0.52–0.93); and grade 3/4 adverse events are 15.4% versus 10.6%. Clinicians note the same unresolved question as three years ago: whether the adjuvant half of the regimen is contributing anything, both in patients achieving pCR and in unselected non-pCR patients. Some argue the absence of an OS benefit here punctures the assumed invincibility of neoadjuvant chemoimmunotherapy, with agent choice, patient selection, and other factors cited as possible explanations.
Discussed by: @HHorinouchi, @OncoAlert, @YGaritaonaindia, @BalazsHalmosMD
PAPILLON reports first-line amivantamab-chemotherapy overall survival in EGFR exon 20 insertion NSCLC at the WCLC26 plenary
PAPILLON's plenary presentation at WCLC26 (PL03.03; NCT04538664) covers first-line amivantamab-chemotherapy versus chemotherapy overall survival in NSCLC with EGFR exon 20 insertions, framed alongside ADAURA, REZILIENT3, and ARROS-1 as part of a theme of targeted therapy moving earlier. In the same first-line population, WU-KONG28 reported that sunvozertinib gave median PFS of 10.3 versus 7.5 months (HR 0.65; P<0.001) and ORR of 58.9% versus 31.1%. With an oral TKI and an amivantamab-chemotherapy regimen both now showing superiority to chemotherapy first line, the question of what should decide initial therapy for EGFR exon 20 insertion NSCLC remains open.
Discussed by: @OncoAlert, @GlopesMd, @ChandrakanthMv
MDT-BRIDGE reports a 74.6% resection rate with neoadjuvant durvalumab plus chemotherapy in resectable and borderline resectable stage IIB-IIIB NSCLC
MDT-BRIDGE reported a resection rate of 74.6%, with pCR 27.3% and 12-month EFS 90.1% in the resectable cohort, using a design that starts neoadjuvant durvalumab plus chemotherapy with close multidisciplinary follow-up — proceeding to surgery then adjuvant durvalumab, or to chemoradiation then consolidation immunotherapy — so that more patients can receive curative-intent treatment. Among alternative locally advanced strategies presented alongside it, SACTION01 neoadjuvant SBRT plus immunochemotherapy reported 48-month EFS of 64.6%, 48-month OS of 81.7%, and pCR of 52.2%. The central debate is whether borderline resectable stage III NSCLC should start induction chemoimmunotherapy with the surgical decision deferred to a multidisciplinary review.
Discussed by: @HHorinouchi, @HHorinouchi, @EladSharonMD
Sutetinib reports a 70.8% response rate in uncommon EGFR mutations, with compound mutations doing best
IRC-confirmed ORR was 70.8%, DCR 90.6%, median duration of response 12.0 months, and median PFS 13.7 months with sutetinib in NSCLC harboring uncommon EGFR mutations; compound mutations showed a higher ORR (84.4%) than solitary uncommon mutations (64.1%). The most common grade 3 or higher treatment-related adverse event was diarrhea at 28%, which sets the practical threshold for deciding whether the activity profile is usable. The debate centers on whether a 70.8% response rate with 13.7-month PFS makes sutetinib the new first-line reference for G719X/S768I/L861Q NSCLC despite that toxicity rate.
Discussed by: @StephenVLiu, @HHorinouchi
🔥 Top Ranked Tweets
OncoAlert @OncoAlert
RT @Dr_ElvinaA: KEYNOTE-671: 5-year results are here.
In resectable stage II–IIIB (N2) NSCLC, perioperative pembrolizumab + chemotherapy showed durable benefit:
• 5-yr EFS: 49.9% vs 26.5% (HR 0.58)
• 5-yr OS: 64.6% vs 53.6% (HR 0.74)
A sustained survival benefit !
@Larvol @OncoAlert https://t.co/l3MLvgb7ub
🔖 0 ❤️ 6 🔁 5 👁 482
Elvina Almuradova @Dr_ElvinaA
KEYNOTE-671: 5-year results are here.
In resectable stage II–IIIB (N2) NSCLC, perioperative pembrolizumab + chemotherapy showed durable benefit:
• 5-yr EFS: 49.9% vs 26.5% (HR 0.58)
• 5-yr OS: 64.6% vs 53.6% (HR 0.74)
A sustained survival benefit !
@Larvol @OncoAlert https://t.co/l3MLvgb7ub
🔖 0 ❤️ 6 🔁 5 👁 482
OncoAlert @OncoAlert
RT @HHorinouchi: 🆙#WCLC26 #LCSM Plenary Session
🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: Primary Results
🎙️ @JuliaRotow
🔢PL03.08
🎯T-DXd Showed Statistically Significant and Clinically Meaningful PFS Improvement vs SOC (Chemo+Pembrolizumab) as First-Line Therapy
☑️NCT05048797
🔗 https://t.co/gAahGHJGeA
@OncoAlert @Larvol @IASLC
🔖 13 ❤️ 46 🔁 20 👁 4,453
Jennifer A. Marks, MD @jennifermarksmd
RT @HHorinouchi: 🆙#WCLC26 #LCSM Plenary Session
🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: Primary Results
🎙️ @JuliaRotow
🔢PL03.08
🎯T-DXd Showed Statistically Significant and Clinically Meaningful PFS Improvement vs SOC (Chemo+Pembrolizumab) as First-Line Therapy
☑️NCT05048797
🔗 https://t.co/gAahGHJGeA
@OncoAlert @Larvol @IASLC
🔖 13 ❤️ 46 🔁 20 👁 4,453
Solange Peters @peters_solange
RT @HHorinouchi: 🆙#WCLC26 #LCSM Plenary Session
🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: Primary Results
🎙️ @JuliaRotow
🔢PL03.08
🎯T-DXd Showed Statistically Significant and Clinically Meaningful PFS Improvement vs SOC (Chemo+Pembrolizumab) as First-Line Therapy
☑️NCT05048797
🔗 https://t.co/gAahGHJGeA
@OncoAlert @Larvol @IASLC
🔖 13 ❤️ 46 🔁 20 👁 4,453
Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista
KEYNOTE-671 at 5 Years: 🫁
Perioperative Pembrolizumab Delivers Durable Survival Benefit in Resectable NSCLC
5-year EFS: 49.9% vs 26.5% (HR 0.58)
5-year OS: 64.6% vs 53.6% (HR 0.74)
https://t.co/cYKpdLFeCY
@OncoAlert #Lcsm @myESMO @ESMO_Open https://t.co/gWtK2j4lUl
🔖 2 ❤️ 21 🔁 8 👁 832
Lung Cancers Today @Lung_Cancers
RT @HHorinouchi: 🆙#WCLC26 #LCSM Plenary Session
🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: Primary Results
🎙️ @JuliaRotow
🔢PL03.08
🎯T-DXd Showed Statistically Significant and Clinically Meaningful PFS Improvement vs SOC (Chemo+Pembrolizumab) as First-Line Therapy
☑️NCT05048797
🔗 https://t.co/gAahGHJGeA
@OncoAlert @Larvol @IASLC
🔖 13 ❤️ 46 🔁 20 👁 4,453
OncoAlert @OncoAlert
RT @RManochakian: 🔥🚨 @OncoAlert Hot off the press.
Just published @Annals_Oncology
⭐️Five-Year Outcomes of #Keynote671
trial of #Perioperative #Pembrolizumab + chemo vs chemo alone in resectable stage II-IIIB non-small cell #LungCancer (#NSCLC).
✅⬆️5-year #EFS
49.9% (pembro arm) vs 26.5% (HR, 0.58)
✅⬆️5-year #OS
64.6% (pembro arm) vs 53.6% (HR, 0.74)
👇🏻
https://t.co/DPEblT4Rry
🔖 2 ❤️ 44 🔁 9 👁 2,428
OncoAlert @OncoAlert
RT @Dr_Oncologista: KEYNOTE-671 at 5 Years: 🫁
Perioperative Pembrolizumab Delivers Durable Survival Benefit in Resectable NSCLC
5-year EFS: 49.9% vs 26.5% (HR 0.58)
5-year OS: 64.6% vs 53.6% (HR 0.74)
https://t.co/cYKpdLFeCY
@OncoAlert #Lcsm @myESMO @ESMO_Open https://t.co/gWtK2j4lUl
🔖 2 ❤️ 21 🔁 8 👁 832
OncoAlert @OncoAlert
RT @OncoAlert: News From Industry: DESTINY Lung-04 🫁 Update in #LungCancer
Source: Daiichi Sankyo
https://t.co/PQ8adGCCFd
DESTINY-Lung04 has reported positive topline Phase 3 results showing trastuzumab deruxtecan significantly and clinically meaningfully improved progression-free survival versus platinum-pemetrexed chemotherapy + pembrolizumab as first-line treatment for patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous NSCLC.
@peters_solange
@christine_lovly
@GlopesMd
@DrSanjayPopat
@StephenVLiu
@HenningWillers
@HHorinouchi
@BRicciutiMD
@PercyLeeMD
@jillfeldman4
@bensolomon1
@Latinamd
@DrJNaidoo
@barlesi
@UOzkerim
@FernandoOnco
@DrMirallas
@VanitaNoronha
@NarjustFlorezMD
@MartinReck2
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@nataliagandur
@GIMedOnc
@DaisukeKotani
🔖 2 ❤️ 16 🔁 8 👁 2,549
Kazuki Nozawa, MD @kazuki_nozawa
RT @dr_yakupergun: Updated KEYNOTE-671 results: 5-year EFS 49.9% vs 26.5%; OS 64.6% vs 53.6% with periop pembro
Yet key questions remain: Who needs neoadjuvant-only vs periop therapy? Is the adjuvant phase needed—and for how long? Can PD-L1, pCR or ctDNA/MRD guide selection?
https://t.co/mb00TcgnAM
🔖 38 ❤️ 85 🔁 26 👁 42,504
Oncology Brothers @OncBrothers
RT @dr_yakupergun: Updated KEYNOTE-671 results: 5-year EFS 49.9% vs 26.5%; OS 64.6% vs 53.6% with periop pembro
Yet key questions remain: Who needs neoadjuvant-only vs periop therapy? Is the adjuvant phase needed—and for how long? Can PD-L1, pCR or ctDNA/MRD guide selection?
https://t.co/mb00TcgnAM
🔖 38 ❤️ 85 🔁 26 👁 42,504
Balazs Halmos @BalazsHalmosMD
Key notes on KN671
☑️Immunotherapy DOUBLES EFS at 5 yrs - ie IO adds as much benefit as surgery/chemo combined!
☑️1/10 pts cured w added IO
☑️while X-trial comparisons challenging, strong benefit for pts without PCR makes consideration of adj IO prudent IMO
☑️Ton of rich data emerging as to nuances in clinic- eg TPS strata/RVT (pts w RVT>60% really should be referred to trials as much as possible…)
Considering no OS benefit yet from adj IO trials, all relevant pts should be considered for neoadj/periop approaches!
#lcsm
Congrats to @HwakeleeMD and team!
Feel lucky we had a chance to contribute/offer this pivotal study to our pts at Monte/Einstein!
[Quoting @dr_yakupergun: Updated KEYNOTE-671 results: 5-year EFS 49.9% vs 26.5%; OS 64.6% vs 53.6% with periop pembro
Yet key questions remain: Who needs neoadjuvant-only vs periop therapy? Is the adjuvant phase needed—and for how long? Can PD-L1, pCR or ctDNA/MRD guide selection?
https://t.co/mb00TcgnAM]
🔖 28 ❤️ 75 🔁 20 👁 7,513
Hidehito HORINOUCHI @HHorinouchi
🔥KEYNOTE-671: 5-year outcomes of perioperative pembrolizumab for early-stage NSCLC
🆙 @Annals_Oncology @myESMO
🎯5-y EFS 49.9 vs 26.5% (HR 0.58, 95% CI, 0.48‒0.69)
🎯5-y OS 64.6 vs 53.6% (HR 0.74, 95% CI, 0.59‒0.92)
🎙 @HwakeleeMD
#LCSM @OncoAlert @Larvol
https://t.co/eaZb5WnfDz
🔖 4 ❤️ 30 🔁 9 👁 1,419
Hidehito HORINOUCHI @HHorinouchi
🆙#WCLC26 #LCSM Plenary Session
🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: Primary Results
🎙️ @JuliaRotow
🔢PL03.08
🎯T-DXd Showed Statistically Significant and Clinically Meaningful PFS Improvement vs SOC (Chemo+Pembrolizumab) as First-Line Therapy
☑️NCT05048797
🔗 https://t.co/gAahGHJGeA
@OncoAlert @Larvol @IASLC
[Quoting @HHorinouchi: 🔥DESTINY-Lung04: "Statistically significant and clinically meaningful improvement in PFS"
🆙 @AstraZeneca @DaiichiSankyo
👥Patients: HER2 exon19/20-mutant, unresectable/locally advanced or metastatic non-squamous NSCLC, 1st-line
3⃣Phase III
⚖️Trastuzumab deruxtecan
⚖️Platinum-pemetrexed doublet + pembrolizumab
🔢NCT05048797
#LCSM @OncoAlert @Larvol
🔗 https://t.co/jWxU9lCT3T]
🔖 13 ❤️ 46 🔁 20 👁 4,453
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.